Atlas Trials

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

Clinical trial NCT05380453 · COMPLETED

Trial details

NCT number
NCT05380453
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Giant Cell Arteritis
Start date
2022-09-29
Primary completion
2026-02-24
Enrollment
151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.